These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1095081)

  • 1. Comparative symptomatological and evoked potential studies with d-amphetamine, thioridazine, and placebo in hyperkinetic children.
    Saletu B; Saletu M; Simeon J; Viamontes G; Itil TM
    Biol Psychiatry; 1975 Jun; 10(3):253-75. PubMed ID: 1095081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-amphetamine and delinquency: hyperkinesis persisting?
    Maletzky BM
    Dis Nerv Syst; 1974 Dec; 35(12):543-7. PubMed ID: 17896753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results.
    Gittelman-Klein R; Klein DF; Katz S; Saraf K; Pollack E
    Arch Gen Psychiatry; 1976 Oct; 33(10):1217-31. PubMed ID: 971031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thioridazine, amphetamine and placebo on the hyperkinetic syndrome and cognitive area in mentally deficient children.
    Alexandris A; Lundell FW
    Can Med Assoc J; 1968 Jan; 98(2):92-6. PubMed ID: 4864657
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
    Gross MD
    Dis Nerv Syst; 1976 Jan; 37(1):14-6. PubMed ID: 1106966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate in hyperkinetic children: differences in dose effects on impulsive behavior.
    Brown RT; Sleator EK
    Pediatrics; 1979 Oct; 64(4):408-11. PubMed ID: 492804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative effects of drugs and diet on hyperactive behaviors: an experimental study.
    Williams JI; Cram DM; Tausig FT; Webster E
    Pediatrics; 1978 Jun; 61(6):811-7. PubMed ID: 353680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders.
    Stotsky B
    Clin Ther; 1984; 6(4):546-59. PubMed ID: 6380725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evoked potential in pharmacopsychiatry.
    Saletu B
    Neuropsychobiology; 1977; 3(2-3):75-104. PubMed ID: 896005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thioridazine in the treatment of depressive patients.
    de Jonghe FE; Schalken HF; van der Helm HJ
    Acta Psychiatr Scand; 1976 Apr; 53(4):271-6. PubMed ID: 775889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonidine treatment of hyperactive and impulsive children with autistic disorder.
    Jaselskis CA; Cook EH; Fletcher KE; Leventhal BL
    J Clin Psychopharmacol; 1992 Oct; 12(5):322-7. PubMed ID: 1479049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of thioridazine dosage on the behavior of severely mentally retarded persons.
    Singh NN; Aman MG
    Am J Ment Defic; 1981 May; 85(6):580-7. PubMed ID: 7023237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of methylphenidate on the soft neurological signs of hyperactive children.
    Lerer RJ; Lerer MP
    Pediatrics; 1976 Apr; 57(4):521-5. PubMed ID: 772581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J; Pliszka SR
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.